Completed PHASE4 INTERVENTIONAL 3-arm NCT01016249

Nebulized 5% Hypertonic Saline for the Treatment of Bronchiolitis

Nebulized 5% Hypertonic Saline for Infirmary Treatment of Acute Infant Bronchiolitis: A Randomized Trial

Sponsor: Hamad Medical Corporation

Interventions Treatment 1. (5% Hypertonic saline + Epinephrine) Treatment 2. (Normal saline + Epinephrine) Treatment 3. (3% Hypertonic saline + Epinephrine)

Updated 4 times since 2017 Last updated: Nov 18, 2009 Started: Apr 30, 2007 Primary completion: Apr 30, 2008 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01016249, this PHASE4 trial focuses on Bronchiolitis and remains completed. Sponsored by Hamad Medical Corporation, it has been updated 4 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hamad Medical Corporation

Data source: Hamad Medical Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Doha, Qatar